UPDATE: Repligen Says Co., Navigo Will Co Develop Portfolio Of Next-Gen Ligands Utilizing Navigo's Proprietary Precision Capturing Technology Platform; Repligen To Receive IP Rights, Exclusivity, But No Further Terms Disclosed